Clinical trial
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
NCT00027027 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00027027 |
|---|---|
| Title | Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors |
| Official title | A Phase I, Open-Label, Multicenter, Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 (rhuMAb 2C4) Administered Every 3 Weeks to Subjects With Advanced Solid Malignancies |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | rhuMAb 2C4 |
| Enrollment | 21 |
| Start date | Nov 1, 2001 |
| Primary completion | Aug 1, 2003 |
| Completion | Aug 1, 2003 |
| First posted | Nov 16, 2001 |
| Last update posted | Jul 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: